Skip to main content

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Reports on Litigation Filed in US District Court Against Capybara Research

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, is reporting on a newly filed lawsuit against Capybara Research. According to the announcement, the company has filed a lawsuit in the United States District Court for the Southern District of New York against Capybara Research; the lawsuit was filed Dec. 20, 2023.

A short-selling research company created in July 2023, Capybara Research creates “short reports” on publicly traded companies and publishes those reports anonymously to its Twitter account and website. Capybara Research “frequently posts inaccurate and misleading information with the intention to antagonize our retail investment community and embarrass the company,” the announcement stated.

Knightscope earlier reported that it has retained dilution funder combatant Mark R. Basile, Esq, and his Securities and RICO litigation firm to assist in investigating and prosecuting claims in defense of the company and its retail investors. The company has reported that after weeks of work by legal counsel combined with third-party cooperation, attorneys have identified the person responsible for the malicious report on Knightscope and are taking all steps necessary to prosecute all responsible parties.

“We are committed to legally pursuing all short and distort campaigns against the company as well as all media outlets that irresponsibly reported the false, misleading and defaming Capybara Report,” said Knightscope chair and CEO William Santana Li in the press release.

To view the full press release, visit https://ibn.fm/FSI5s

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.